Results 201 to 210 of about 108,225 (293)

Proton Pump Inhibitor Use and Incident Hypertension in Menopausal Women. [PDF]

J Am Heart Assoc
Soliman AI, Wactawski-Wende J, Millen AE, Gray SL, Eaton CB, Hovey KM, Donneyong M, Saquib N, Mouton CP, Laddu D, Liu S, Shimbo D, Wassertheil-Smoller S, LaMonte MJ.   +13 more
europepmc   +1 more source

Transfersomes with core and surface‐loaded NF‐κB p65 siRNA for enhanced transdermal transfection and effective treatment of psoriasis

BMEMat, EarlyView.
TCPL, a transfersome with Tween 80 and PEI, enables efficient transdermal siNF‐κB delivery, resolving PEI's toxicity issue. It promotes lysosomal escape and effective transfection, silences NF‐κB, modulates immunity, and inhibits angiogenesis, alleviating psoriasis. With good biocompatibility, TCPL holds strong clinical translation potential. Schematic
Hui Xing, Yuhui Yang, Ziyi Zhao, Kai Lv, Yiran Shao, Zhi Zhang, Dong Ma   +6 more
wiley   +1 more source

Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study. [PDF]

BMC Cancer
Miyamoto I, Shimizu T, Hanamura M, Tanaka R, Kusahana R, Nomoto M, Sugaya K, Nakagawa Y, Gon Y.   +8 more
europepmc   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

The Prognostic Impact of Multiple Adverse Events on Long‐Term Mortality Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh, Yong Hee Kim, Eun Ho Choo, Kwan Yong Lee, Ik Jun Choi, Jong‐Min Lee, Ki‐Dong Yoo, Mahn‐Won Park, Chul Soo Park, Hee‐Yeol Kim, Min Chul Kim, Youngkeun Ahn, Kiyuk Chang   +12 more
wiley   +1 more source

Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.

JAMA Netw Open
Le Rhun E, Sain D, Erridge SC, Reardon DA, Minniti G, Roth P, Wick W, Nabors B, Sampson J, Mason W, Cloughesy T, Reijneveld JC, Stupp R, Preusser M, Gorlia T, Weller M.   +15 more
europepmc   +1 more source

Unique epithelial proliferative transcriptomic signature in proton pump inhibitor-responsive pediatric eosinophilic esophagitis. [PDF]

JCI Insight
Chakraborty S, Sharma A, Marella S, Rizza CF, O'Brien PA, Ganesan V, Idelman G, Min S, Chen M, McCright-Gill T, Gonzalez N, Polydorides AD, Foster PS, Hogan SP, Chehade M.   +14 more
europepmc   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

Appropriateness of proton pump inhibitor prescription for prevention of gastrointestinal bleeding in patients receiving warfarin: a real world, database study. [PDF]

BMC Pharmacol Toxicol
Manasirisuk P, Sawanyawisuth K, Manasirisuk W.   +2 more
europepmc   +1 more source

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source